Larimar Therapeutics Holds 2025 Annual Stockholders Meeting

Larimar Therapeutics ( (LRMR) ) has shared an announcement.

On May 13, 2025, Larimar Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders virtually, where several key proposals were voted on. Thomas E. Hamilton was elected as a Class II director, the compensation for the company’s executive officers in 2024 was approved, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2025. These outcomes reflect the company’s ongoing governance and operational strategies, potentially impacting its future direction and stakeholder confidence.

The most recent analyst rating on (LRMR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.

Spark’s Take on LRMR Stock

According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.

Larimar Therapeutics’ stock score reflects its early-stage biotech status with high R&D costs, no consistent revenue, and reliance on equity financing. Despite positive short-term technical indicators suggesting upward momentum, the lack of profitability and a negative P/E ratio weigh heavily on the stock. Valuation concerns and the absence of earnings call insights further impact the score.

To see Spark’s full report on LRMR stock, click here.

More about Larimar Therapeutics

Larimar Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for rare diseases. The company is involved in the research and development of therapeutics aimed at addressing unmet medical needs.

Average Trading Volume: 1,021,007

Technical Sentiment Signal: Sell

Current Market Cap: $133.2M

See more data about LRMR stock on TipRanks’ Stock Analysis page.